
Takeda Pharmaceuticals: Global Homepage
This website provides information about Takeda's worldwide business. For specific information about our local markets, please use the country selector.
United States | Home - Takeda
Apr 30, 2025 · Welcome to Takeda in the U.S. We’re the largest life sciences employer in the state of Massachusetts with our global hub and research center in Cambridge, MA., and have sites across …
Takeda Careers | Explore Job Openings & Apply Online
At Takeda, we're united by a shared purpose and proud of our work. We aspire to be part of something bigger than any one person.
About Our Company | Takeda Pharmaceuticals
Takeda's vision is to discover and deliver life-transforming treatments guided by our commitment to patients, our people, and the planet.
About us | Takeda U.S.
About Takeda in the United States We are a global, values-based, R&D-driven biopharmaceutical leader with a large U.S. presence. We connect to our 240+ year-old history and Japanese heritage through …
Our Products | Takeda Pharmaceuticals
Each of our local websites may provide more information about products available in the respective country or region. Health Care Professionals (HCPs) can also access the Takeda Global Medical …
Working at Takeda Pharmaceutical
Takeda's recruiting correspondence will be sent by a recruiting representative with @takeda.com email address — not @gmail.com, @yahoo.com, @hotmail.com or any other email domain service. We …
Research and Development | Takeda Pharmaceuticals
Takeda's R&D efforts are focused on discovering, developing and delivering life-transforming medicines for rare and more prevalent diseases across Oncology, Neuroscience and Gastrointestinal and …
Research and Development | United States - Takeda
Takeda and its Alliance partners are committed to supporting high-quality, un-biased, evidence-based independent medical education for healthcare professionals, teams, patients, payers and systems.
Takeda Announces First-Quarter FY2025 Results With Significant Late ...
Jul 30, 2025 · Takeda announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVANSE significantly impacting revenue and Core …